SENS Elliot Wave analysis
Updated
It looks like wave 2 has completed for SENS. They had a conference today march 9th about some things that were already known to us, but they made some things more clear. Quick summary of this conference:
- Accuracy of the current device is best in class with a MARD of 8.5%
- Medicare National Coverage as of Jan 1, 2021:
- Avg "Supply Cost" (I assume this is for the hardware and consumables) : $1571
- CPT Code 0446T (device insertion) $1,916 average payment
- CPT Code 0448T (device removal and insertion) $1,926 average payment
- Ascencia's commercial world wide investment in Senseonics product marketing is expected to be 330M-
80M per year over 5 years (this is where they got the 250M in the previous conference) and expect the US Ascencia personnel assigned to Senseonics to be in the 80-160 range.
- Eversense is Ascencia's first CGM product and they have exclusive rights to the sales and distribution.
Product Pipeline:
2021+ : Eversense 180 and iCGM/interoperability (integrate with insulin pumps)
2023 : Eversense 365, 1 calibration/week, optional FGM (flash glucose monitoring - no transmitter needed)
2024 : Freedom System, FGM, entire diabetes spectrum covered out to T2 non-insulin using patients.
(credits for this summary to ww.reddit.com/r/senseonics/comments/m18cxq/sens_hc_wainwright_conference_takeaways/)
I'm now looking for a 5 structure to the upside for a wave 3.
Pricetarget for wave 3 is around $10.
How long this will take I'm not sure.
- Accuracy of the current device is best in class with a MARD of 8.5%
- Medicare National Coverage as of Jan 1, 2021:
- Avg "Supply Cost" (I assume this is for the hardware and consumables) : $1571
- CPT Code 0446T (device insertion) $1,916 average payment
- CPT Code 0448T (device removal and insertion) $1,926 average payment
- Ascencia's commercial world wide investment in Senseonics product marketing is expected to be 330M-
80M per year over 5 years (this is where they got the 250M in the previous conference) and expect the US Ascencia personnel assigned to Senseonics to be in the 80-160 range.- Eversense is Ascencia's first CGM product and they have exclusive rights to the sales and distribution.
Product Pipeline:
2021+ : Eversense 180 and iCGM/interoperability (integrate with insulin pumps)
2023 : Eversense 365, 1 calibration/week, optional FGM (flash glucose monitoring - no transmitter needed)
2024 : Freedom System, FGM, entire diabetes spectrum covered out to T2 non-insulin using patients.
(credits for this summary to ww.reddit.com/r/senseonics/comments/m18cxq/sens_hc_wainwright_conference_takeaways/)
I'm now looking for a 5 structure to the upside for a wave 3.
Pricetarget for wave 3 is around $10.
How long this will take I'm not sure.
Comment
looks like wave 2 of wave 3 is in now
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.